REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE

被引：0
|
作者：
Lam, J. [1 ]
Lin, V. W. [2 ]
Purdum, A. G. [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] Kite, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.227
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN103
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT).
    Ghosh, Nilanjan
    Emond, Bruno
    Lafeuille, Marie-Helene
    Cote-Sergent, Aurelie
    Lefebvre, Patrick
    Huang, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study
    Ghosh, Nilanjan
    Emond, Bruno
    Lafeuille, Marie-Helene
    Cote-Sergent, Aurelie
    Lefebvre, Patrick
    Huang, Qing
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1285 - 1299
  • [3] Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients
    Kozma, Chris M.
    Slaton, Terra
    Ellis, Lorie
    McKenzie, R. S.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China
    Cai, Qingqing
    Huang, Huiqiang
    Zhang, Yuchen
    Liu, Panpan
    Jing, Hongmei
    Yang, Ping
    Lin, Tongyu
    Xia, Zhongjun
    Li, Zhiming
    Li, Wenyu
    Zhong, Liye
    Ye, Xu
    Jin, Xueli
    Zhang, Liling
    Zhang, Huilai
    Sun, Xiuhua
    Tian, Yuyang
    Ma, Shuyun
    Su, Ning
    Cai, Jun
    BLOOD, 2020, 136
  • [6] Mantle Cell Lymphoma (MCL) Treatment Patterns, Healthcare Resource Use (HRU), and Costs in the United States
    Kozma, Chris
    Slaton, Terra
    McKenzie, R. Scott
    Schenkel, Brad
    Ellis, Lode
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S226 - S226
  • [7] Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark
    Trab, Trine
    Chanchiri, Iman
    Al-Mashhadi, Ahmed
    Berggreen, Emma
    Rasch, Stine
    Johansen, Mette
    Husby, Simon
    Clausen, Michael Roost
    Larsen, Thomas Stauffer
    Desseau-Arp, Andriette C.
    Christensen, Jacob Haaber
    Pedersen, Robert Schou
    Frederiksen, Mikael
    Brown, Peter de Nully
    El-Galaly, Tarec Christoffer
    Gronbaek, Kirsten
    BLOOD, 2024, 144 : 6325 - 6326
  • [8] REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS FOR RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) AND MONOCLONAL ANTIBODIES (MAB) THERAPIES
    Feng, C.
    Murphy, L.
    Engel-Nitz, N.
    Nguyen, A.
    Patel, A.
    DuCharme, M.
    Fu, C.
    Shah, G.
    VALUE IN HEALTH, 2023, 26 (06) : S395 - S395
  • [9] Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
    Jeon, Young-Woo
    Yoon, Seugyun
    Min, Gi June
    Park, Sung-Soo
    Park, Silvia
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Min, Chang-Ki
    Lee, Jong Wook
    Cho, Seok-Goo
    CANCER MEDICINE, 2019, 8 (16): : 6860 - 6870
  • [10] Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among US Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment
    Squires, Patrick
    Puckett, Justin T.
    Ryland, Katherine Elizabeth
    Kamal-Bahl, Sachin
    Raut, Monika
    Doshi, Jalpa A.
    Huntington, Scott F.
    BLOOD, 2023, 142
12345